RT Journal Article
SR Electronic
T1 Characterization of the Metabolites of Carbamazepine in Patient Urine by Liquid Chromatography/Mass Spectrometry
JF Drug Metabolism and Disposition
JO Drug Metab Dispos
FD American Society for Pharmacology and Experimental Therapeutics
SP 275
OP 280
VO 25
IS 3
A1 Maggs, J. L.
A1 Pirmohamed, M.
A1 Kitteringham, N. R.
A1 Park, B. K.
YR 1997
UL http://dmd.aspetjournals.org/content/25/3/275.abstract
AB The urinary metabolites of carbamazepine (CBZ) in epileptic patients receiving long-term drug treatment have been characterized by LC/MS. CBZ-10,11-epoxide (9.6–15.0 μg/ml),trans-10,11-dihydrodiol-CBZ (273.0–400.00 μg/ml), and CBZ (2.4–3.8 μg/ml) were measured by HPLC. The secondaryN-glucuronide of CBZ, four phenolicO-glucuronides (including those of 2- and 3-OH-CBZ), two additional OH-CBZ O-glucuronides, and theN-glucuronide of CBZ-10,11-epoxide constituted the products of either direct conjugation or preliminary monoxygenation. Derivatives of these monoxygenated compounds, which were characterized asO-glucuronides, were represented by dihydroxylated (catechol) CBZ and its putative O-methyl metabolite and by 10,11-dihydrodiol-CBZ. 10,11-Dihydro-10-OH-CBZO-glucuronide, a metabolite thought to be excreted only by uremic subjects, was not found. More complicated biotransformations of the 10,11-ene moiety were revealed by two carbinol products of azepine ring contraction: 9-OH-methyl-10-carbamoyl acridan and an hydroxylated derivative thereof, which were excreted as O-glucuronides. No polar sulfur-containing metabolites that might serve as indicators of reactive intermediate formation were found in human urine. The American Society for Pharmacology and Experimental Therapeutics